UnipharLSE:UPR -4.15%84 EBITDA Margin % is 4.39% as of Dec. 2025, which is 21% above its 10-year median of 3.64. GuruFocus rates LSE:UPR with a GF Score™ of 84/100 and a GF Value™ of £3.03 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 119 Medical Distribution companies, Uniphar ranks worse than 56.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Uniphar's EBITDA for the
six
months ended in Dec. 2025 was £61 Mil. Uniphar's Revenue for the
six
months ended in Dec. 2025 was £1,390 Mil. Therefore, Uniphar's EBITDA margin for the quarter that ended in Dec. 2025 was 4.39%.
Uniphar (LSE:UPR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Uniphar EBITDA Margin % Related Terms
Uniphar EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Uniphar's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:UPR vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Uniphar's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Uniphar's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar (LSE:UPR) has a EBITDA Margin % of 4.39% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Uniphar and its competitors. This is 21% above median its historical median of 3.64. Over the past decade, Uniphar's EBITDA Margin % has ranged from 0.55 to 4.94. According to the industry distribution chart, Uniphar ranks #67 out of 119 companies in the Medical Distribution industry, placing it in the top 56.3%.
Is Uniphar's EBITDA Margin % too high?
Uniphar's current EBITDA Margin % of 4.39% is 21% above median its 10-year median of 3.64. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 4.94. The Medical Distribution industry median EBITDA Margin % is 4.31. Uniphar's value of 4.39% is 1.9% above this industry median. Based on the distribution chart, Uniphar ranks #67 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Uniphar has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #67 out of 119 companies for EBITDA Margin %. This places Uniphar in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Uniphar's value of 4.39% is 1.9% above this benchmark. Historically, Uniphar's own EBITDA Margin % has ranged from 0.55 to 4.94 over the past decade. While the company's 10-year median is 3.64 vs. the industry median of 4.31, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current EBITDA Margin % of 4.39% is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current EBITDA Margin % is 4.39%, which is 21% above median its own 10-year median of 3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (LSE:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is £3.03, compared to a current price of £3.93 — trading 29.7% above its estimated fair value. The current EBITDA Margin % is 4.39%, which is 21% above median its 10-year median of 3.64 and 1.9% above the Medical Distribution industry median of 4.31. Uniphar's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Uniphar (LSE:UPR), the current EBITDA Margin % is 4.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (LSE:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of £3.93 is trading 29.7% above its estimated GF Value™ of £3.03.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for LSE:UPR:
EBITDA Margin %: 4.39% (21% above median its 10-year median of 3.64)
GF Value™: £3.03 vs. price of £3.93 (29.7% above fair value)
Industry Position: 1.9% above the Medical Distribution median (#67 of 119)
No single metric tells the full story. See the LSE:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
84GF Score
Get the complete analysis for LSE:UPR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:UPR has been successfully added to your 
